,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,179,1,1,,67640,679,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
1,180,1,1,,67640,679,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Adenocarcinoma 755 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
2,186,1,1,,67640,679,Unspecified,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Nontumored Animals (Toxicity Test) in B6D2F1 (BDF1) mice,Other,,
3,192,1,1,,67640,679,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
4,194,1,1,,67640,679,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
5,196,1,1,,67640,679,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intracerebral) in B6D2F1 (BDF1) mice,Other,,
6,206,1,1,,67640,679,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
7,212,1,1,,67640,679,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
8,220,1,1,,67640,679,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Mammary Adenocarcinoma CD8F1 (subcutaneous) in CD8F1,Other,,
9,222,1,1,,67640,679,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Ependymoblastoma (intracerebral) in C57BL/6 mice,Other,,
10,226,1,1,,67640,679,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Ependymoblastoma (intracerebral) in B6C3F1 mice,Other,,
11,248,1,1,,67640,679,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
12,250,1,1,,67640,679,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
13,252,1,1,,67640,679,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intracerebral) in B6D2F1 (BDF1) mice,Other,,
14,256,1,1,,67640,679,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
15,260,1,1,,67640,679,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intracerebral) in CD2F1 (CDF1) mice,Other,,
16,266,1,1,,67640,679,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Lung LX-1 Xenograft (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
17,270,1,1,,67640,679,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
18,274,1,1,,67640,679,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intravenous) in B6D2F1 (BDF1) mice,Other,,
19,298,1,1,,67640,679,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
20,328,1,1,,67640,679,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
21,330,1,1,,67640,679,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
22,334,1,1,,67640,679,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intracerebral) in CD2F1 (CDF1) mice,Other,,
23,342,1,1,,67640,679,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma 180 (subcutaneous) in Swiss mice,Other,,
24,1188,1,2,,48414927,679,Active,,,,,DSSTox (EPAFHM) EPA Fathead Minnow Acute Toxicity,Other,,
25,1469,1,1,,26757375,679,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
26,1479,1,2,,26757375,679,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
27,30246,6,4,,103172948,679,Unspecified,,,25000.0,Ki,Compound was evaluated for reversible inhibition of hydrolysis acetylcholine by acetylcholinesterase and represented as KI(com),Confirmatory,4032433.0,
28,37570,5,3,,103172948,679,Inactive,,,,,Antifungal activity against Aspergillus niger MTCC 404 measured through zone of inhibition; Inactive,Other,15203169.0,
29,40332,5,3,,103172948,679,Inactive,,,,,Antibacterial activity against Bacillus cereus MTCC 1272 measured through zone of inhibition; Inactive,Other,15203169.0,
30,40616,3,3,,103172948,679,Inactive,,,,,Effect on Bacillus subtilis in plate diffusion test; No growth inhibition,Other,11755347.0,
31,40793,5,2,,103172948,679,Inconclusive,,,,,Minimum inhibitory concentration against Bacillus subtilis; n.d.=not determined,Other,11755347.0,
32,40954,5,3,,103172948,679,Inactive,,,,,Antibacterial activity against Bacillus subtilis MTCC 121 measured through zone of inhibition; Inactive,Other,15203169.0,
33,46907,5,3,,103172948,679,Inactive,,,,,Antifungal activity against Candida albicans MTCC 183 measured through zone of inhibition; Inactive,Other,15203169.0,
34,69151,3,3,,103172948,679,Unspecified,,,,,"Compound was tested for its ability to inhibit DNA strand scission induced by resveratrol and Cu2+, at concentration 50 mM",Other,9873700.0,
35,70300,5,3,,103172948,679,Inactive,,,,,Antibacterial activity against Escherichia coli MTCC 42 measured through zone of inhibition; Inactive,Other,15203169.0,
36,70559,4,4,,103172948,679,Unspecified,,,,,Percent benzidine-positive cell differentiation in friend erythroleukemia cells,Other,3862866.0,
37,70686,4,4,,103172948,679,Unspecified,,,,,Optimum concentration for differentiation of friend erythroleukemia cells,Other,3862866.0,
38,71649,3,4,,103172948,679,Unspecified,,,,,Inhibitory activity against cellular differentiation in Friend erythroleukemia cells as percentage of benzidine - positive cells.,Other,3861870.0,
39,71651,3,4,,103172948,679,Unspecified,,,,,Inhibitory activity against cellular differentiation in Friend erythroleukemia cells as optimal concentration required for maximum activity.,Other,3861870.0,
40,71652,3,4,,103172948,679,Unspecified,,,,,The degree of erythroid maturation was measured by assessing the proportion of benzidine-positive cells at a concentration of 210 mM,Other,6793727.0,
41,71654,3,4,,103172948,679,Unspecified,,,,,The degree of erythroid maturation was measured by assessing the proportion of benzidine-positive cells at a concentration of 4 mM,Other,6793727.0,
42,71661,3,4,,103172948,679,Unspecified,,,,,Cell growth of friend erythroleukemia cells measured as percentage of control on day 6 at a concentration of 105 mM,Other,6793727.0,
43,71666,3,4,,103172948,679,Unspecified,,,,,Effect on the replication and erythroid differentiation of friend leukemia cells on day 3 at a concentration of 210 mM,Other,6793727.0,
44,71667,3,4,,103172948,679,Unspecified,,,,,Effect on the replication and erythroid differentiation of friend leukemia cells on day 6 at a concentration of 210 mM,Other,6793727.0,
45,71669,3,4,,103172948,679,Unspecified,,,,,Percent of untreated control cell growth evaluated in friend leukemia cells on day 3 at a concentration of 105 mM,Other,6793727.0,
46,81812,3,4,,103172948,679,Unspecified,,,,,Differentiating activity of compound in HL60 cells at conc 1.4 ug/mL,Other,9371251.0,
47,81815,3,4,,103172948,679,Unspecified,,,,,Differentiating activity of compound in HL60 cells at conc 2.8 ug/mL,Other,9371251.0,
48,81817,3,4,,103172948,679,Unspecified,,,,,Differentiating activity of compound in HL60 cells at conc 5.6 ug/mL,Other,9371251.0,
49,82143,3,4,,103172948,679,Unspecified,,,,,"Percent of differentiated HL-60 cells was determined by dividing number of viable differentiated cells by total number of viable cells, at a concentration of 38 mM",Other,3806621.0,
50,82145,3,4,,103172948,679,Unspecified,,,,,"Percent of differentiated HL-60 cells was determined by dividing number of viable differentiated cells by total number of viable cells, at a concentration of 64 mM",Other,3806621.0,
51,82146,3,4,,103172948,679,Unspecified,,,,,"Percent of differentiated HL-60 cells was determined by dividing number of viable differentiated cells by total number of viable cells, at a concentration of 77 mM",Other,3806621.0,
52,82479,3,4,,103172948,679,Unspecified,,,,,"Percent of viability for HL-60 cells was determined by dividing number of viable differentiated cells by total number of viable cells, at concentration of 38 mM",Other,3806621.0,
53,82481,3,4,,103172948,679,Unspecified,,,,,"Percent of viability for HL-60 cells was determined by dividing number of viable differentiated cells by total number of viable cells, at concentration of 64 mM",Other,3806621.0,
54,82482,3,4,,103172948,679,Unspecified,,,,,"Percent of viability for HL-60 cells was determined by dividing number of viable differentiated cells by total number of viable cells, at concentration of 77 mM",Other,3806621.0,
55,82488,3,4,,103172948,679,Unspecified,,,,,"Differentiation studies was conducted with the HL-60 human myeloid leukemia cell line and Total cells were counted with a Coulter counter, at a concentration of 64 mM",Other,3806621.0,
56,82489,3,4,,103172948,679,Unspecified,,,,,"Differentiation studies was conducted with the HL-60 human myeloid leukemia cell line and Total cells were counted with a Coulter counter, at a concentration of 77 mM",Other,3806621.0,
57,82492,3,4,,103172948,679,Unspecified,,,,,"Differentiation studies was conducted with the HL-60 human myeloid leukemia cell line and total cells were counted with a Coulter counter, at a concentration of 38 mM",Other,3806621.0,
58,93219,6,4,,103172948,679,Unspecified,,,719000.0,Kd,Dissociation constant in BS binding to Insulin-like growth factor binding protein 5 at the residue K91,Confirmatory,12477349.0,
59,93234,6,4,,103172948,679,Unspecified,,,541000.0,Kd,Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue L73,Confirmatory,12477349.0,
60,93235,6,4,,103172948,679,Unspecified,,,610000.0,Kd,Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue L81,Confirmatory,12477349.0,
61,93236,6,4,,103172948,679,Unspecified,,,921000.0,Kd,Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue R87,Confirmatory,12477349.0,
62,93237,6,4,,103172948,679,Unspecified,,,650000.0,Kd,Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue S85,Confirmatory,12477349.0,
63,93238,6,4,,103172948,679,Unspecified,,,648000.0,Kd,Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue Y50,Confirmatory,12477349.0,
64,93239,6,4,,103172948,679,Unspecified,,,783000.0,Kd,Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue Y86,Confirmatory,12477349.0,
65,135485,3,4,,103172948,679,Unspecified,,,,,Number of animals survived when the compound was tested at a dose of 30 mgkg/day in 5 Swiss mice,Other,8057301.0,
66,139290,3,3,,103172948,679,Unspecified,,,,,Percentage of weight gained or lost in 1 week in normal swiss mice at a dose of 30 mg/kg/day,Other,8057301.0,
67,139291,3,3,,103172948,679,Unspecified,,,,,Percentage of weight gained or lost in 2nd week in normal swiss mice at a dose of 30 mg/kg/day,Other,8057301.0,
68,139292,3,3,,103172948,679,Unspecified,,,,,Percentage of weight gained or lost in 3rd week in normal swiss mice at a dose of 30 mg/kg/day,Other,8057301.0,
69,139293,3,3,,103172948,679,Unspecified,,,,,Percentage of weight gained or lost in 4th week in normal swiss mice at a dose of 30 mg/kg/day,Other,8057301.0,
70,146720,3,4,,103172948,679,Unspecified,,,,,Effect on cell cycle (G0/G1 phase) progression by flow cytometry against NUGC3 human cancer cells after 24 hours,Other,12036364.0,
71,146721,3,4,,103172948,679,Unspecified,,,,,Effect on cell cycle (G2/M phase) progression by flow cytometry against NUGC3 human cancer cells after 24 hours,Other,12036364.0,
72,146722,3,4,,103172948,679,Unspecified,,,,,Effect on cell cycle (S-phase) progression by flow cytometry against NUGC3 human cancer cells after 24 hours,Other,12036364.0,
73,148819,4,10,,103172948,679,Unspecified,730228.0,100135587.0,,,Inhibition against Opioid receptor kappa 1 using selective ligand [3H]U-69593,Other,9857089.0,
74,163761,5,3,,103172948,679,Inactive,,,,,Antibacterial activity against Pseudomonas aeruginosa MTCC 1034. measured through zone of inhibition; Inactive,Other,15203169.0,
75,174673,3,3,,103172948,679,Unspecified,,,,,Serum concentration of LH 12 days after intravenous administration in Orchidectomized rats,Other,3531516.0,
76,174674,3,3,,103172948,679,Unspecified,,,,,Serum concentration of LH 18 days after intravenous administration in Orchidectomized rats,Other,3531516.0,
77,174675,3,3,,103172948,679,Unspecified,,,,,Serum concentration of LH 24 days after intravenous administration in Orchidectomized rats,Other,3531516.0,
78,174676,3,3,,103172948,679,Unspecified,,,,,Serum concentration of estradiol 12 days after intravenous administration in Orchidectomized rats,Other,3531516.0,
79,174677,3,3,,103172948,679,Unspecified,,,,,Serum concentration of estradiol 18 days after intravenous administration in Orchidectomized rats,Other,3531516.0,
80,174678,3,3,,103172948,679,Unspecified,,,,,Serum concentration of estradiol 24 days after intravenous administration in Orchidectomized rats,Other,3531516.0,
81,203282,5,3,,103172948,679,Inactive,,,,,Antibacterial activity against Staphylococcus aureus MTCC 1430 measured through zone of inhibition; Inactive,Other,15203169.0,
82,251652,4,1,,103172948,679,Unspecified,,,,,Zone of inhibition of Escherichia coli after treatment with the compound,Other,15686887.0,
83,251676,4,1,,103172948,679,Unspecified,,,,,Zone of inhibition of Staphylococcus aureus after treatment with the compound,Other,15686887.0,
84,251680,4,1,,103172948,679,Unspecified,,,,,Zone of inhibition of Pseudomonas aeruginosa after treatment with the compound,Other,15686887.0,
85,252072,3,3,,103172948,679,Unspecified,,,,,Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 1 mg/mL after incubation for 24 hr,Other,15713399.0,
86,252073,4,2,,103172948,679,Unspecified,,,,,Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 1 mg/mL after incubation for 48 hr,Other,15713399.0,
87,252074,3,3,,103172948,679,Unspecified,,,,,Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 1 mg/mL after incubation for 72 hr,Other,15713399.0,
88,252075,3,3,,103172948,679,Unspecified,,,,,Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 1 mg/mL after incubation for 98 hr,Other,15713399.0,
89,252077,3,3,,103172948,679,Unspecified,,,,,Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 10 mg/mL after incubation for 24 hr,Other,15713399.0,
90,252078,3,3,,103172948,679,Unspecified,,,,,Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 10 mg/mL after incubation for 48 hr,Other,15713399.0,
91,252079,3,3,,103172948,679,Unspecified,,,,,Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 10 mg/mL after incubation for 72 hr,Other,15713399.0,
92,252080,3,3,,103172948,679,Unspecified,,,,,Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 10 mg/mL after incubation for 98 hr,Other,15713399.0,
93,252082,3,3,,103172948,679,Unspecified,,,,,Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 100 mg/mL after incubation for 24 hr,Other,15713399.0,
94,252083,3,3,,103172948,679,Unspecified,,,,,Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 100 mg/mL after incubation for 48 hr,Other,15713399.0,
95,252084,3,3,,103172948,679,Unspecified,,,,,Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 100 mg/mL after incubation for 72 hr,Other,15713399.0,
96,252085,3,3,,103172948,679,Unspecified,,,,,Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 100 mg/mL after incubation for 98 hr,Other,15713399.0,
97,288694,6,2,,103172948,679,Unspecified,,,,GI50,Growth inhibition of human HT29 cells after 48 hrs,Confirmatory,17498960.0,
98,288695,6,2,,103172948,679,Unspecified,,,,GI50,Growth inhibition of human M21 cells after 48 hrs,Confirmatory,17498960.0,
99,288696,6,2,,103172948,679,Unspecified,,,,GI50,Growth inhibition of human MCF7 cells after 48 hrs,Confirmatory,17498960.0,
100,552438,5,3,,103172948,679,Unspecified,,,,,Cytotoxicity against mouse HII4E cells after 48 hrs by MTT assay,Other,21215645.0,
101,565856,1,4,,103172948,679,Unspecified,,,,,Cell cycle arrest in human NCI-H460 cells assessed as accumulation at G0/G1 phase at GI50 after 48 hrs by flow cytometry,Other,21138784.0,
102,565857,1,4,,103172948,679,Unspecified,,,,,Cell cycle arrest in human NCI-H460 cells assessed as accumulation at S phase at GI50 after 48 hrs by flow cytometry,Other,21138784.0,
103,565858,1,4,,103172948,679,Unspecified,,,,,Cell cycle arrest in human NCI-H460 cells assessed as accumulation at G2/M phase at GI50 after 48 hrs by flow cytometry,Other,21138784.0,
104,565859,1,4,,103172948,679,Unspecified,,,,,Induction of apoptosis in human NCI-H460 cells at GI50 after 48 hrs by V-FITC/propidium iodide staining-based flow cytometry,Other,21138784.0,
105,588211,2,3,,103172948,679,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
106,588212,2,3,,103172948,679,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
107,588213,2,3,,103172948,679,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
108,588513,1,1,,26757375,679,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
109,588514,1,1,,26757375,679,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
110,588515,1,1,,26757375,679,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
111,588516,1,1,,26757375,679,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
112,588526,1,1,,26757375,679,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
113,588527,1,1,,26757375,679,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
114,588532,1,1,,26757375,679,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
115,588533,1,1,,26757375,679,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
116,588534,1,1,,26757375,679,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
117,588535,1,1,,26757375,679,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
118,588536,1,1,,26757375,679,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
119,588537,1,1,,26757375,679,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
120,588541,1,1,,26757375,679,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
121,588543,1,1,,26757375,679,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
122,588544,1,1,,26757375,679,Inconclusive,325495497.0,6256.0,19952.6,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
123,588545,1,1,,26757375,679,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
124,588546,1,1,,26757375,679,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
125,588547,1,1,,26757375,679,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
126,605243,1,8,,103172948,679,Inactive,2497561.0,25054.0,,,Agonist activity at TrkB in E17 rat primary cortical neurons assessed as AKT phosphorylation at Ser 473 at 500 nM after 15 mins by ELISA,Other,21073191.0,
127,625144,5,5,,103172948,679,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
128,625145,4,7,,103172948,679,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
129,625146,5,5,,103172948,679,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
130,625147,4,7,,103172948,679,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
131,625148,4,7,,103172948,679,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
132,625149,4,7,,103172948,679,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
133,625150,5,5,,103172948,679,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
134,625151,4,7,,103172948,679,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
135,625152,4,7,,103172948,679,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
136,625153,4,7,,103172948,679,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
137,625154,4,7,,103172948,679,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
138,625155,4,7,,103172948,679,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
139,625156,1,9,,103172948,679,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
140,625157,6,2,,103172948,679,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
141,625158,3,4,,103172948,679,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
142,625159,5,5,,103172948,679,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
143,625160,1,9,,103172948,679,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
144,625161,4,7,,103172948,679,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
145,625162,4,7,,103172948,679,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
146,625163,4,7,,103172948,679,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
147,625164,1,6,,103172948,679,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
148,625165,3,4,,103172948,679,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
149,625166,3,4,,103172948,679,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
150,625167,5,5,,103172948,679,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
151,625168,4,7,,103172948,679,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
152,625169,1,6,,103172948,679,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
153,625170,3,4,,103172948,679,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
154,625171,4,7,,103172948,679,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
155,625172,4,7,,103172948,679,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
156,625173,5,5,,103172948,679,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
157,625174,5,5,,103172948,679,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
158,625175,5,5,,103172948,679,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
159,625176,1,9,,103172948,679,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
160,625177,5,5,,103172948,679,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
161,625178,5,5,,103172948,679,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
162,625179,1,9,,103172948,679,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
163,625180,5,5,,103172948,679,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
164,625181,5,5,,103172948,679,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
165,625182,5,5,,103172948,679,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
166,625183,5,5,,103172948,679,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
167,625184,5,5,,103172948,679,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
168,625185,5,5,,103172948,679,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
169,625186,5,5,,103172948,679,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
170,625187,5,5,,103172948,679,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
171,625188,1,9,,103172948,679,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
172,625189,1,7,,103172948,679,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
173,625190,4,5,,103172948,679,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
174,625191,4,7,,103172948,679,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
175,625192,4,7,,103172948,679,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
176,625193,5,5,,103172948,679,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
177,625194,4,7,,103172948,679,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
178,625195,4,7,,103172948,679,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
179,625196,5,6,,103172948,679,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
180,625197,3,4,,103172948,679,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
181,625198,4,7,,103172948,679,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
182,625199,4,7,,103172948,679,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
183,625200,4,7,,103172948,679,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
184,625201,4,7,,103172948,679,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
185,625202,4,7,,103172948,679,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
186,625203,4,7,,103172948,679,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
187,625204,4,7,,103172948,679,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
188,625205,4,7,,103172948,679,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
189,625206,4,7,,103172948,679,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
190,625207,4,7,,103172948,679,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
191,625208,5,5,,103172948,679,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
192,625209,4,7,,103172948,679,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
193,625210,3,4,,103172948,679,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
194,625211,1,6,,103172948,679,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
195,625212,3,4,,103172948,679,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
196,625213,4,7,,103172948,679,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
197,625214,1,9,,103172948,679,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
198,625215,3,4,,103172948,679,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
199,625216,3,4,,103172948,679,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
200,625217,4,7,,103172948,679,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
201,625218,4,7,,103172948,679,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
202,625219,3,4,,103172948,679,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
203,625220,4,7,,103172948,679,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
204,625221,4,7,,103172948,679,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
205,625222,4,7,,103172948,679,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
206,625223,4,7,,103172948,679,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
207,625224,3,4,,103172948,679,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
208,625225,3,4,,103172948,679,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
209,625226,4,7,,103172948,679,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
210,625227,4,7,,103172948,679,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
211,625228,4,7,,103172948,679,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
212,625229,5,5,,103172948,679,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
213,625230,1,6,,103172948,679,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
214,625231,4,7,,103172948,679,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
215,625232,1,9,,103172948,679,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
216,625233,4,7,,103172948,679,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
217,625234,3,4,,103172948,679,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
218,625235,4,7,,103172948,679,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
219,625236,5,5,,103172948,679,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
220,625237,4,7,,103172948,679,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
221,625238,4,7,,103172948,679,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
222,625239,4,7,,103172948,679,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
223,625240,1,9,,103172948,679,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
224,625241,4,7,,103172948,679,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
225,625242,4,7,,103172948,679,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
226,625243,5,5,,103172948,679,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
227,625244,5,5,,103172948,679,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
228,625245,5,5,,103172948,679,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
229,625246,1,9,,103172948,679,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
230,625247,5,5,,103172948,679,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
231,625248,5,5,,103172948,679,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
232,625249,5,5,,103172948,679,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
233,625250,5,5,,103172948,679,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
234,625251,5,5,,103172948,679,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
235,625252,4,7,,103172948,679,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
236,625253,4,7,,103172948,679,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
237,625254,4,7,,103172948,679,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
238,625255,4,7,,103172948,679,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
239,625256,4,7,,103172948,679,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
240,625257,4,7,,103172948,679,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
241,625258,4,7,,103172948,679,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
242,625259,4,7,,103172948,679,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
243,625260,3,4,,103172948,679,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
244,625261,3,4,,103172948,679,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
245,625262,3,4,,103172948,679,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
246,625263,4,7,,103172948,679,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
247,625264,3,4,,103172948,679,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
248,625265,1,6,,103172948,679,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
249,625266,3,4,,103172948,679,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
250,625267,3,4,,103172948,679,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
251,625268,4,2,,103172948,679,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
252,625268,4,2,,103172948,679,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
253,625268,4,2,,103172948,679,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
254,625268,4,2,,103172948,679,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
255,625269,4,7,,103172948,679,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
256,625270,4,7,,103172948,679,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
257,625271,5,5,,103172948,679,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
258,625272,3,4,,103172948,679,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
259,625273,4,6,,103172948,679,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
260,625274,1,6,,103172948,679,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
261,625275,3,4,,103172948,679,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
262,625294,1,3,,103172948,679,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data,Other,22194678.0,
263,651631,4,1,,144211274,679,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
264,651632,4,1,,144211274,679,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
265,651633,4,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
266,651634,4,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
267,651741,1,1,,26757375,679,Inconclusive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
268,651743,1,1,,26757375,679,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
269,651749,1,1,,26757375,679,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
270,651751,1,1,,26757375,679,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
271,651777,1,1,,26757375,679,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
272,651778,1,1,,26757375,679,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
273,651838,1,1,,26757375,679,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
274,651838,1,1,1.0,26757375,679,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
275,651838,1,1,2.0,26757375,679,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
276,651838,1,1,3.0,26757375,679,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
277,651838,1,1,4.0,26757375,679,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
278,651838,1,1,5.0,26757375,679,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
279,651838,1,1,6.0,26757375,679,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
280,651838,1,1,7.0,26757375,679,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
281,651838,1,1,8.0,26757375,679,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
282,720516,2,1,,144211274,679,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
283,720552,2,1,,144211274,679,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
284,720634,2,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
285,720635,2,1,,144211274,679,Inconclusive,,,6.859,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
286,720636,1,1,,26757375,679,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
287,720637,2,1,,144211274,679,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
288,720653,1,1,,26757375,679,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
289,720659,1,1,,26757375,679,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
290,720674,2,2,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
291,720675,2,2,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
292,720678,2,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
293,720679,2,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
294,720680,2,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
295,720681,2,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
296,720682,2,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
297,720683,2,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
298,720684,2,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
299,720685,2,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
300,720686,2,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
301,720687,2,2,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
302,720691,4,1,,144211274,679,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
303,720692,3,1,,144211274,679,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
304,720693,3,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
305,720719,2,1,,144211274,679,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
306,720725,2,1,,144211274,679,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
307,743012,3,1,,144211274,679,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
308,743014,3,1,,144211274,679,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
309,743015,3,1,,144211274,679,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
310,743033,3,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
311,743035,2,1,,144211274,679,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
312,743036,2,1,,144211274,679,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
313,743040,3,1,,144211274,679,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
314,743041,3,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
315,743042,3,1,,144211274,679,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
316,743053,2,1,,144211274,679,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
317,743054,2,1,,144211274,679,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
318,743063,2,1,,144211274,679,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
319,743064,3,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
320,743065,3,1,,144211274,679,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
321,743066,3,1,,144211274,679,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
322,743067,2,1,,144211274,679,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
323,743069,2,1,,144211274,679,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
324,743074,2,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
325,743075,2,1,,144211274,679,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
326,743077,2,1,,144211274,679,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
327,743078,2,1,,144211274,679,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
328,743079,3,1,,144211274,679,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
329,743080,3,1,,144211274,679,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
330,743081,3,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
331,743083,3,1,,144211274,679,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
332,743084,3,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
333,743085,3,1,,144211274,679,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
334,743086,3,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
335,743091,2,1,,144211274,679,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
336,743094,3,1,,144211274,679,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
337,743122,2,1,,144211274,679,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
338,743139,2,1,,144211274,679,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
339,743140,2,1,,144211274,679,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
340,743191,3,1,,144211274,679,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
341,743194,3,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
342,743199,2,1,,144211274,679,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
343,743202,4,1,,144211274,679,Inconclusive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
344,743203,3,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
345,743209,3,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
346,743210,4,1,,144211274,679,Inconclusive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
347,743211,3,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
348,743212,3,1,,144211274,679,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
349,743213,3,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
350,743215,3,1,,144211274,679,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
351,743217,3,1,,144211274,679,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
352,743218,3,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
353,743219,3,1,,144211274,679,Active,20149576.0,4780.0,61.1306,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
354,743220,3,1,,144211274,679,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
355,743221,3,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
356,743222,3,1,,144211274,679,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
357,743223,3,1,,144211274,679,Inconclusive,216409708.0,7421.0,0.0138,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
358,743224,3,1,,144211274,679,Inconclusive,,,54.941,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
359,743225,3,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
360,743226,2,1,,144211274,679,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
361,743227,2,1,,144211274,679,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
362,743228,3,1,,144211274,679,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
363,743239,2,1,,144211274,679,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
364,743240,2,1,,144211274,679,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
365,743241,2,1,,144211274,679,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
366,743242,2,1,,144211274,679,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
367,743288,1,1,,26757375,679,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
368,743292,1,1,,26757375,679,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
369,1078155,1,4,,103172948,679,Unspecified,20141192.0,23476.0,280000.0,IC50,Inhibition of BRD4(1) (unknown origin) by Alpha screen binding assay,Confirmatory,,
370,1136153,1,1,,103172948,679,Unspecified,,,,,Induction of erythroid differentiation in DBA/2J mouse Friend erythroleukemia cells assessed as concentration required for maximum proportion of benzidine positive cells after 6 days,Other,281531.0,
371,1136154,1,1,,103172948,679,Unspecified,,,,,Induction of erythroid differentiation in DBA/2J mouse Friend erythroleukemia cells assessed as cell growth after 3 days relative to control,Other,281531.0,
372,1136155,1,1,,103172948,679,Unspecified,,,,,Induction of erythroid differentiation in DBA/2J mouse Friend erythroleukemia cells assessed as benzidine positive cells after 6 days relative to control,Other,281531.0,
373,1136156,1,1,,103172948,679,Unspecified,,,,,Induction of erythroid differentiation in DBA/2J mouse Friend erythroleukemia cells assessed as hemoglobin level per 10'7 cells after 3 to 6 days relative to control,Other,281531.0,
374,1159509,1,1,,144211274,679,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
375,1159515,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
376,1159516,1,1,,144211274,679,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
377,1159517,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
378,1159518,1,1,,144211274,679,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
379,1159519,1,1,,144211274,679,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
380,1159520,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
381,1159521,1,1,,144211274,679,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
382,1159523,1,1,,144211274,679,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
383,1159525,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
384,1159526,1,1,,144211274,679,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
385,1159527,1,1,,144211274,679,Inconclusive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
386,1159528,1,1,,144211274,679,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
387,1159529,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
388,1159531,1,1,,144211274,679,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
389,1159551,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
390,1159552,1,1,,144211274,679,Inactive,325495463.0,5914.0,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
391,1159553,2,1,,144211274,679,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
392,1159555,1,1,,144211274,679,Inconclusive,325495463.0,5914.0,54.4827,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
393,1159620,1,1,,103172948,679,Active,,,,,Summary of drug indications.,Other,,
394,1224834,3,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
395,1224835,1,1,,144211274,679,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
396,1224836,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
397,1224837,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
398,1224838,1,1,,144211274,679,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
399,1224839,1,1,,144211274,679,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
400,1224840,3,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
401,1224841,3,1,,144211274,679,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
402,1224842,3,1,,144211274,679,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
403,1224843,1,1,,144211274,679,Inconclusive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
404,1224844,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
405,1224845,1,1,,144211274,679,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
406,1224846,1,1,,144211274,679,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
407,1224847,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
408,1224848,3,1,,144211274,679,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
409,1224849,3,1,,144211274,679,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
410,1224863,1,1,,316919445,679,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
411,1224867,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
412,1224868,1,1,,144211274,679,Inconclusive,,,61.6448,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
413,1224869,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
414,1224870,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
415,1224871,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
416,1224872,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
417,1224873,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
418,1224874,1,1,,144211274,679,Inconclusive,,,54.941,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
419,1224875,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
420,1224876,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
421,1224877,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
422,1224878,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
423,1224879,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
424,1224880,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
425,1224881,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
426,1224882,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
427,1224883,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
428,1224884,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
429,1224885,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
430,1224886,1,1,,144211274,679,Inconclusive,,,54.941,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
431,1224887,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
432,1224888,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
433,1224889,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
434,1224890,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
435,1224892,1,1,,144211274,679,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
436,1224893,1,1,,144211274,679,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
437,1224894,1,1,,144211274,679,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
438,1224895,1,1,,144211274,679,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
439,1224896,1,1,,144211274,679,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
440,1259241,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
441,1259242,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
442,1259243,1,1,,144211274,679,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
443,1259244,1,1,,144211274,679,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
444,1259247,1,1,,144211274,679,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
445,1259248,1,1,,144211274,679,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
446,1259364,1,1,,144211274,679,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
447,1259365,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
448,1259366,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
449,1259367,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
450,1259368,1,1,,144211274,679,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
451,1259369,1,1,,144211274,679,Active,109731339.0,2737.0,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
452,1259377,1,1,,144211274,679,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
453,1259378,1,1,,144211274,679,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
454,1259379,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
455,1259380,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
456,1259381,1,1,,144211274,679,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
457,1259382,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
458,1259383,1,1,,144211274,679,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
459,1259384,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
460,1259385,1,1,,144211274,679,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
461,1259386,1,1,,144211274,679,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
462,1259387,1,1,,144211274,679,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
463,1259388,1,1,,144211274,679,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
464,1259390,1,1,,144211274,679,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
465,1259391,1,1,,144211274,679,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
466,1259392,1,1,,144211274,679,Inconclusive,109731339.0,2737.0,68.5896,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
467,1259393,1,1,,144211274,679,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
468,1259394,1,1,,144211274,679,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
469,1259395,1,1,,144211274,679,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
470,1259396,1,1,,144211274,679,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
471,1259401,1,1,,144211274,679,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
472,1259402,1,1,,144211274,679,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
473,1259403,1,1,,144211274,679,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
474,1259404,1,1,,144211274,679,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
475,1259407,1,1,,363898893,679,Inactive,,,,,CCRIS mutagenicity studies,Other,,
476,1259408,1,1,,363894953,679,Inactive,,,,,GENE-TOX mutagenicity studies,Other,,
